The UK has some of the world’s most exciting science, a supportive business environment, a vibrant financial sector and strong companies led by experienced management teams. The UK is building something great – a global bioscience cluster that delivers life-changing treatments for patients in the National Health Service, rewarding and high-paying R&D and manufacturing jobs for people across the UK, and sustainable long-term economic growth for the country. The UK is recognised as a world leader in the life sciences, and the sector contributed £30.4bn to the UK economy in 2015 and supported 482,000 jobs, according to a recent report by PwC.
- UK has the strongest and most robust clinical pipeline in Europe: The number of drug products in clinical development (or in registration with regulators) is higher in the UK than anywhere else in Europe.
- UK leads Europe in venture capital funding and is gaining on US clusters: UK companies received £680 million in venture capital in 2016, more than a third of the total venture capital raised in Europe and more than any other European country.
UK BioIndustry Association (BIA)
Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative life sciences in the UK. Our goal is to secure the UK’s position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people’s lives.
Leading Innovation – The UK’s ATMP Landscape
The Alliance for Regenerative Medicine (ARM) and the BioIndustry Association (BIA) have published a report setting out the scope of the UK’s robust and growing Advanced Therapy Medicinal Products (ATMPs) sector, which includes the development of potentially transformative cell and gene therapies.See Publication
Global and Growing: UK Biotech Financing in 2019
New figures by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveal that the UK biotech sector raised £1.3 billion in 2019. The total is the third highest year recorded by the trade association and since 2012 investment has increased by over 400%.See Publication
Engineering Biology Explained
Engineering Biology Explained: A guide to engineering biology and UK excellence in the field.See Publication
Confident Capital: Backing UK Biotech
This Report released by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveals that the UK biotech sector raised a record £2.2 billion from investors in 2018. The total is the best ever recorded by the trade association and almost double that raised in 2017.See Publication
Cell and Gene Therapy Explained
Cell and Gene Therapy Explained: A guide to cell and gene therapy and UK excellence in the field.See Publication
Antimicrobial Resistance Explained: A Guide to Antimicrobial Resistance and How UK Excellence is Helping Tackle this Global Ghallenge
Antibiotics are a triumph of modern medicine. Alexander Fleming’s famously serendipitous discovery of penicillin during the 1920s led to one of the most effective treatments for bacterial infections, still in use today. But the success of penicillin and many other antibiotics developed since has created an entirely new, arguably even bigger healthcare challenge, that of antimicrobial resistance (AMR).
Bacteria have learned to out-smart antimicrobial molecules and have developed resistance. Bacteria reproduce and evolve far faster than humans and most animals, and they can share helpful DNA easily among each other, not just with their offspring.
This document explains more on AMR and what BIA member companies are doing to tackle it.See Publication
A Vision for the UK Life Sciences Sector in 2025
This report provides a roadmap for the growth of the UK biotechnology industry.See Publication
A Guide to Genomics
Genomics Explained: A guide to genomics and UK excellence in the field.See Publication